What’s new for ICH Q9 and ICH Q12?

04.10.2021

LOGFILE Feature

A report from the 2021 PDA/FDA Joint Regulatory Conference

7 min. reading time | by Sabine Paris, PhD
Published in LOGFILE 38/2021

The PDA/FDA Joint Regulatory Conference, which is now in its 30th year, took place as a virtual event from September 27 – September 29. The Conference focused on the role of effective quality systems in ensuring an ongoing state of control throughout the product lifecycle by vigilantly managing risks to manufacturing and quality.

The session ICH’s Initiatives to Advance Global Harmonization, Innovation, and Continual Improvement Throughout Lifecycle highlighted the revision of ICH Q9 and the implementation of ICH Q12.

Kevin O’Donnell, Market Compliance Manager from the Irish authority HPRA, gave an update on the ongoing revision of ICH Q9 on Quality Risk Management (QRM).

“QRM is a fundamental enabler for the Pharmaceutical Quality System,“ he opened his presentation. The initial discussions for a revision of ICH Q9 started in 2018. HPRA, EMA, an U.S. FDA colleague and an industry representative were involved and prepared the first proposal. The European Commision made a formal proposal to ICH for a revision in 2019. By November 2019, ICH made a decision to proceed with this suggested revision. The finalisation of the revised guideline is currently anticipated for May 2022.

The revision concerns 6 specific topics:

Subjectivity in QRM
Product Availability Risks
Formality in QRM
Risk-based Decision Making
Risk Review
Hazard Identification

These topics will be addressed by adding new guidance that an by developing special training materials. Only for „Risk Review“ ICH Q9’s guidance is sufficient, but training materials will be developed, too.

“This is a very targeted revision of ICH Q9 – it is not a full rewrite. Most of the existing guidance will remain unchanged.“

Scientific approaches to QRM are also stressed in the Concept Paper for the revision. Another area of focus are new technologies and innovation in so far that the revision may support digitisation and emerging technologies, automation, and use of big data, PAT. Furthermore, quality defect issues are mentioned three times in the Concept Paper. This reflects that there are still unmitigated risks as a result of quality defects.

“Why do we need ICH Q12?“ Frank Montgomery from AstraZeneca asked in his enlightening talk about the implementation of ICH Q12 on pharmaceutical product lifecycle management. The need for ICH Q12 results from acceleration of clinical development. The CMC development goes beyond submission. The final supply chain or optimal devices are often introduced post-approval. Thus, the number of post-approval changes (PACs) has also been accelerated. The company’s portfolios are much more diverse than in former days. Another trigger for developing ICH Q12 is the diverse global regulatory environment for PACs. The total expected approval lead time for a world wide approval may even take up to 4 years!

AstraZeneca has already done a succesful ICH Q12 pilot submission in the U.S. for an oral product. They introduced established conditions (ECs) for the synthetic drug substance. The biopharmaceutical risk and impact to the drug product from changes to API were low. The benefits of introducing the tools ECs and PLCM were:

Site change for drug substance was enabled by agreement of ECs and agreement on necessary supporting stability. Confirmatory stability data were provided rather than in application. The change could be implemented 6 month earlier than usually.
Serveral process changes progressed without immediate reporting.
Potential to simplify process via PQS.
Potential simplification of addition of starting material manufacturers.

Exceptional circumstances call for exceptional action! Frank Montgomery reported that for AstraZeneca’s COVID vaccine the approval for a new drug substance site was approved in 7 calendar days!

A look at the worldwide progress on implementation of ICH Q12 revealed that up to now only the U.S. has published a national implementation document. All other regions are still in the middle of the process or are considering a pilot progam.

Editor's note:

The European Commission (EC) emphasized that the already existing legal framework always takes precedence over technical and scientific guidelines. Some of ICH Q12’s tools and concepts are not foreseen in the EU legal framework (e.g. definition of ECs, PLCM). They will be considered when this framework will be reviewed. However, in the meantime, the EC is working on the implementation of ICH Q12 within the existing framework.

Do you have any questions or suggestions? Please contact us at: redaktion@gmp-verlag.de

Dr. Sabine Paris Written on 4 October 2021

You may also be interested in the following articles:

24.11.2025

Question of the Week

How is a QRM process initiated?

You can view the answer here:

FDA: Updated Pre-RFD Guidance for Combination Products

The U.S. FDA has released an updated final guidance on preparing a Pre-Request for Designation (Pre-RFD), replacing the previous 2018 version. The revised document provides new recommendations for interacting with the Office of Combination Products (OCP) and clarifies expectations for Pre-RFD submissions.

EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

The EDQM has introduced a modular training programme covering chemically defined active substances and medicinal products. It will take place between 1 and 12 December 2025.

Related Products

GMP Compliance Adviser | Named User Licence | 12M

The GMP Compliance Adviser is an online publication that covers all aspects of Good Manufacturing Practice (GMP) in one source.In the GMP Compliance Adviser you’ll find: GMP in Practice This part contains 21 chapters with GMP expert knowledge to base your decisions upon. It provides practical assistance with checklists, templates and SOP examples. It is written by more than 80 authors with hands-on experience directly linked to the industry. The individual chapters describe the different aspects of GMP in clear language. Technical, organizational and procedural aspects are covered.More than 700 checklists, templates and examples of standard operation procedures taken directly out of practice help you in understanding the GMP requirements.GMP RegulationsThese chapters cover the most important GMP regulations from Europe and the United States (CFR and FDA), but also PIC/S, ICH, WHO and many more. Sample Documents In addition, the GMP Compliance Adviser contains many sample documents and practical examples that you can use.

Ready for dispatch, Delivery time appr. 2-5 workdays (2-3 weeks for christmas goodies)

€1,335.00 net excl. VAT

Details

GMP:KnowHow Pharma Logistics (GDP) | Named User License | 12M

Your knowledge base about GDP-compliant handling of your pharmaceutical logistics. It is important that you as a logistics service provider, but also as a client in the pharmaceutical industry, adhere precisely to the regulatory requirements. The GMP:KnowHow knowledge portal guides you through the regulatory jungle of the pharmaceutical and logistical supply chain! The knowledge portal gives you an easy-to-understand overview of all the important topics. Using graphics, you can easily navigate through all the areas covered by the EU GDP Guidelines (2013/C 343/01). You also have the relevant passages of the regulations directly at hand for each topic. This allows you to compare the requirements directly and saves you a lot of time on time-consuming searches and research!One thing is certain: the knowledge portal answers your questions about the supply chain of medicinal products, active pharmaceutical ingredients and medical devices. You don't have to be an expert. Yet.You will find answers to your questions in the GMP:KnowHow Pharma Logistics (GDP). Where does GDP begin, where does GMP end? What does GDP-compliant mean? When do I also have to take GMP requirements into account? What permits do I need for certain activities? What requirements do I have to fulfil? What is the current legal basis? How am I covered? What authorizations do I have for my work, e.g. from my employer? Who is responsible — the client or the contractor? And many more What is the difference to the GMP Compliance Adviser? The GMP:KnowHow Pharma Logistics (GDP) is your guideline for Good Distribution Practice. It is a product that is independent of the GMP Compliance Adviser and concentrates on content that is essential for carriers of medicinal products, active pharmaceutical ingredients and medical devices as well as for logistics clients. The focus is on practical knowledge and how to apply it in your daily business. If necessary, the relevant regulations can be called up immediately alongside the practical knowledge, and you can see the relevant paragraphs at a glance. In addition, sample documents are available to help you make immediate progress. AuthorSimone Ferrante – now Director Quality at Fisher Clinical Services – was previously Head of Quality Control and Responsible Person according to GDP (VP) for the entire Grieshaber Group. She is also a long-standing author and GDP expert at GMP-Verlag.

Ready for dispatch, Delivery time appr. 2-5 workdays (2-3 weeks for christmas goodies)

€610.00 net excl. VAT

Details

E-Learning GMP:READY | GMP for Engineers Online Course

Why are GMP rules important for technicians and engineers? Technicians and engineers play a key role in ensuring compliance with Good Manufacturing Practice (GMP) standards. They are involved in critical activities such as: planning and construction of ventilation systems, maintenance of water treatment plants, calibration of measuring sensors. Therefore, they are jointly responsible for the quality of medicines and must ensure that their work complies with GMP standards.Your advantages: Fast familiarization with GMP topics in approx. 2 hours, time- and location-independent online training, printable personal certificate, 12-month access for initial and follow-up training, automatic updates in case of legal changes, content compliant with Article 7(4) of Directive 2003/94/EC.

Ready for dispatch, Delivery time appr. 2-5 workdays (2-3 weeks for christmas goodies)

€240.00 net excl. VAT

Details

GMP Fundamentals | A Step-by-Step Guide

This handbook is a practical and easy to read guideline, giving you a quick and comprehensive overview of the complex world of Good Manufacturing Practice (GMP) without the need of previously acquired knowledge. Some topics are: GMP: Purpose and basic pharmaceutical terms Laws, licenses and inspections Personnel: Responsibility and hygiene Standard Operating Procedures (SOP) and documentation Design of rooms and facilities Processing and packaging Quality control and market release Suppliers, storage and logistics (Good Distribution Practice = GDP) Alphabetical index and abbreviations Using practical examples and comparisons to every-day life will help to easy understand GMP regulations.GMP Fundamentals is a helpful guide which facilitates the entry into the GMP world and teaches the necessary basics.

Ready for dispatch, delivery immediately after receipt of payment

€44.90 net excl. VAT

Details